NCT04630288 is a clinical trial of Clopidogrel in Acute Coronary Syndromes, sponsored by Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud.

What drugs are being tested in NCT04630288?

Interventions in NCT04630288: Clopidogrel, Ticagrelor.

What condition does NCT04630288 study?

NCT04630288 studies Acute Coronary Syndromes.

Is NCT04630288 still recruiting?

NCT04630288 is currently status unknown. Last updated 16 November 2020.

Last reviewed 2020-11-16 · How we verify

NCT04630288

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome

Status unknown Last updated 16 November 2020

What this trial tests

trial testing Clopidogrel in Acute Coronary Syndromes in 1,900 participants. Status unknown.

Timeline

2 July 2019

Primary endpoint
1 November 2019

31 December 2020

Quick facts

Lead sponsor	Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,900
Start date	2 July 2019
Primary completion	1 November 2019
Estimated completion	31 December 2020
Sites	2 locations across Spain

Drugs / interventions tested

Clopidogrel (clopidogrel) — full drug profile →
Ticagrelor (ticagrelor) — full drug profile →

Conditions studied

Acute Coronary Syndromes — all drugs for Acute Coronary Syndromes →

Sponsor

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud — full company profile →

Who can join

18 and older, any sex, with Acute Coronary Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter post-approval observational retrospective cohort study in routine clinical practice (Real World Evidence Study) to assess the 1-year safety profile associated with ticagrelor and clopidogrel therapy in a contemporary reprospective cohort of patients who survived the initial 30-day period after the index hospitalization for acute coronary syndrome (ACS).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparative Safety and Effectiveness of Ticagrelor versus Clopidogrel in Patients With Acute Coronary Syndrome: An On-Treatment Analysis From a Multicenter Registry.
Almendro-Delia M, Blanco-Ponce E, Carmona-Carmona J, Arboleda Sánchez JA, et al · · 2022 · cited 7× · PMID 35711382 · DOI 10.3389/fcvm.2022.887748

Verify or expand the search:

Other trials of Clopidogrel

Trials testing the same drug.

NCT07012629 — A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in P · Phase 3 · recruiting
NCT07025148 — Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding · Phase 4 · recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06757764 — The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis · Phase 4 · recruiting
NCT07040787 — Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Acute Coronary Syndromes

Currently open trials in the same condition.

NCT07123181 — Oregano and Basil Leaves and Coronary Artery Disease · NA · recruiting
NCT06927739 — Focused Orticumab Research for Treating Inflammation in Coronary Arteries · Phase 2 · recruiting
NCT06845826 — Point-of-Care Troponin Testing in the Emergency Department · NA · recruiting
NCT07268859 — Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea · NA · recruiting
NCT06954103 — Mechanisms And Prognosis of Stroke-Heart Syndrome · recruiting

Other Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud trials

Trials by the same sponsor.

NCT02687646 — Clinical Trial With MSC for Graft Versus Host Disease Treatment · Phase 1, PHASE2 · completed
NCT02290041 — Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response · Phase 1, PHASE2 · completed
NCT01765244 — Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanc · Phase 1, PHASE2 · completed
NCT02033278 — Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in P · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04630288 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Last refreshed: 16 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630288.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing